Details for New Drug Application (NDA): 062751
✉ Email this page to a colleague
NDA 062751 describes C-SOLVE-2, which is a drug marketed by Fougera Pharms and Ivax Sub Teva Pharms and is included in two NDAs. Additional details are available on the C-SOLVE-2 profile page.
The generic ingredient in C-SOLVE-2 is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
The generic ingredient in C-SOLVE-2 is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
Summary for 062751
| Tradename: | C-SOLVE-2 |
| Applicant: | Ivax Sub Teva Pharms |
| Ingredient: | erythromycin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062751
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SWAB;TOPICAL | Strength | 2% | ||||
| Approval Date: | Jul 30, 1993 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
